Straits Times Index
3,323.38 +0.18 (+0.01%) S&P 500
5,266.95 -39.09 (-0.74%) Dow
38,441.54 -411.32 (-1.06%) Nasdaq
16,920.58 -99.30 (-0.58%) Bitcoin USD
67,593.18 -64.55 (-0.10%) CMC Crypto 200
1,451.05 -4.82 (-0.33%)
Almirall, S.A. (ALME.XC)
| Previous close | 9.57 |
| Open | 9.57 |
| Bid | 9.32 x N/A |
| Ask | 9.45 x N/A |
| Day's range | 9.57 - 9.57 |
| 52-week range | 7.87 - 9.57 |
| Volume | |
| Avg. volume | 46 |
| Market cap | 2.026B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.20 |
| Earnings date | 22 Jul 2024 |
| Forward dividend & yield | 0.18 (1.92%) |
| Ex-dividend date | 17 May 2024 |
| 1y target est | N/A |
Business WireAlmirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
BARCELONA, Spain, May 13, 2024--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered strong sales growth in the first quarter of 2024 which continues to be driven by the dermatology business in Europe. Net Sales increased by 6.6% to a total of €247.4 MM, EBITDA was €52.5 MM (increase of 1.4% YoY) driven by higher sales growth, with a gross margin of 63.5%. Dermatology sales in Europe incr
GlobeNewswireAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) BARCELONA, Spain and W
Business WireAlmirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
BARCELONA, Spain, February 19, 2024--Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828. Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases.
